Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR-NK019 in Refractory/Relapsed CNS Lymphoma
NCT06827782Phase 1Enrolling by invitation
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Mar 2025
- Primary completion
- Dec 2026
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of CAR-NK019 in central nervous system lymphoma, sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Started Mar 2025; status: enrolling by invitation.
02
Drugs
CAR-NK019
03
Conditions
central nervous system lymphoma
Beyond the preview
Go deeper on NCT06827782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06827782.